ABSTRACT
We evaluated the risk for the Spanish Olympic Team acquiring Zika virus in Rio de Janeiro, Brazil, during 2016. We recruited 117 team members, and all tested negative for Zika virus. Lack of cases in this cohort supports the minimum risk estimates made before the Games.
Subject(s)
Sports , Travel , Zika Virus Infection/epidemiology , Zika Virus Infection/virology , Zika Virus , Anniversaries and Special Events , Athletes , Brazil , Disease Outbreaks/prevention & control , Global Health , Humans , Risk Assessment , SpainSubject(s)
Borrelia burgdorferi , Lyme Disease/diagnosis , Adult , Disease Progression , Erythema/etiology , Erythema/pathology , Female , Humans , Lyme Disease/complications , Time FactorsABSTRACT
Background Fever of intermediate duration (FID) is a common condition. Currently, its most frequent causes are not well defined. Methods Prospective study of FID cases attended at a hospital in 2 periods: 19831989 and 20042005. Blood cultures and serologic studies for Brucella melitensis, Coxiella burnetii, Rickettsia typhi, Rickettsia conorii, cytomegalovirus, and Epstein-Barr virus were performed on all patients. Other microbiological, serological, radiological, or invasive procedures were performed according to clinician-in-charge criteria. Results A total of 505 patients were included from 1983 to 1989, and 179 from 2004 to 2005. A diagnosis was reached in 410 (81.1%) and 109 patients (60.9%), respectively. The cause of FID was an infectious disease in 389 patients from the first period (94.8% of those with a final diagnosis) and 92 from the second (84.4%). Most were systemic infections, 328 (80%) in 19831989 and 74 (67.8%) in 20042005, followed by focal infections, 9.5% and 16.5%, respectively. Q fever was the most frequent etiology in both periods. In 20042005, brucellosis decreased and HIV infection emerged as a cause of FID. The origin of FID was non-infectious in 5.1% and 15.5%, respectively. Conclusions Q fever is the most frequent cause of FID in southern Spain. Studies over time are needed to identify changes in the etiologic spectrum of this condition. Important viral etiologies, such as HIV infection, may be detected as causes of FID. Further studies are needed to determine the importance of other agents as causes of FID (AU)
Introducción La fiebre de duración intermedia (FDI) es una causa importante de fiebre. Las etiologías más importantes no están bien definidas en la actualidad. Métodos Estudio prospectivo de los casos de FDI atendidos entre 19831989 y 20042005. Se realizaron cultivos y estudios serológicos para la detección de Brucella melitensis, Coxiella burnetii, Rickettsia typhi, Rickettsia conorii, citomegalovirus y virus de Epstein-Barr en todos los pacientes. Se llevaron a cabo otros estudios microbiológicos, serológicos, radiológicos y pruebas invasivas adicionales según el criterio del clínico responsable. Resultados En el periodo de 1983 a 1989 se incluyeron 505 pacientes y 179 desde 2004 a 2005. Se alcanzó un diagnóstico etiológico en 410 (81,1%) y 109 (60,9%), respectivamente. La causa de FDI fue infecciosa en 389 pacientes del primer periodo (94,8% del total de pacientes con diagnóstico etiológico) y 92 del segundo (84,4%). La mayoría fueron infecciones sistémicas, 328 (80%) en 19831989 y 74 (67,8%) en 20042005, seguidas de infecciones focales, 9,5% y 16,5%, respectivamente. La fiebre Q fue la etiología más frecuente en ambos periodos. En 20042005, la brucelosis disminuyó mientras que la infección por el VIH se mostró como una causa emergente de FDI. El origen de la FDI fue no infeccioso en el 5,1% y el 15,5% de los casos, respectivamente. Conclusiones La fiebre Q es la causa más frecuente de FDI en el sur de España. Son necesarios estudios prospectivos más amplios para identificar los cambios en el espectro etiológico de esta entidad. Infecciones virales, como la infección por el VIH, deben ser contempladas como causa de FDI (AU)
Subject(s)
Humans , Male , Adult , Fever/etiology , Prospective Studies , Time Factors , Fever/diagnosis , Fever/microbiologyABSTRACT
La infección por Trypanosoma cruzi (T. cruzi), agente responsable de la enfermedad de Chagas, ha estado tradicionalmente ligada a las zonas rurales de América Latina, donde es transmitido por diversas especies de chinches. Esta situación epidemiológica ha ido cambiando en el transcurso de las últimas décadas, de forma que en la actualidad la enfermedad de Chagas es una patología importada diagnosticada a nivel urbano y un problema de salud pública en países no endémicos con gran número de población inmigrante, dónde la transmisión se puede producir durante el embarazo/parto, por transfusión sanguínea o por transplante de órganos. Se estima que hasta un 20% de los pacientes con infección por T. cruzi presentan afectación del aparato digestivo, que causa importante morbilidad y que requiere un manejo y tratamiento adecuado. En el presente documento se aborda el diagnóstico, manejo y tratamiento de las manifestaciones digestivas de pacientes con infección por T. cruzi en nuestro medio (AU)
Trypanosoma cruzi (T. cruzi) infection, causal agent of Chagas disease, has been traditionally limited to rural areas of Latinamerica, where it is transmitted by insects belonging to different species of bugs. Due to recent trends in migration, Chagas disease is now a public health problem in urban areas of endemic countries and in non endemic countries as well, where the transmission via blood products, transplantation of infected organs, or vertical transmission is possible. It is estimated that 20% of individuals infected with T. cruzi might develop symptomatic gastrointestinal disease, which causes important morbidity and needs an adequate management and treatment. The aim of this document is to improve patient care by increasing understanding among physicians and other healthcare professionals who may be involved in the management of patients infected by T. cruzi who present with gastrointestinal symptoms (AU)
Subject(s)
Humans , Chagas Disease/complications , Megacolon/etiology , Esophageal Achalasia/etiology , Trypanosoma cruzi/pathogenicity , Risk Factors , Endemic Diseases , /epidemiologySubject(s)
Humans , Chagas Disease/complications , Esophageal Diseases/parasitology , Gastrointestinal Diseases/parasitology , Chagas Disease/diagnosis , Chagas Disease/therapy , Esophageal Diseases/diagnosis , Esophageal Diseases/therapy , Combined Modality Therapy , Comorbidity , Diagnostic Techniques, Digestive System , Emigrants and Immigrants/statistics & numerical data , Endoscopy, Digestive System , Gastrointestinal Diseases/diagnosis , Gastrointestinal Diseases/therapyABSTRACT
BACKGROUND: Fever of intermediate duration (FID) is a common condition. Currently, its most frequent causes are not well defined. METHODS: Prospective study of FID cases attended at a hospital in 2 periods: 1983-1989 and 2004-2005. Blood cultures and serologic studies for Brucella melitensis, Coxiella burnetii, Rickettsia typhi, Rickettsia conorii, cytomegalovirus, and Epstein-Barr virus were performed on all patients. Other microbiological, serological, radiological, or invasive procedures were performed according to clinician-in-charge criteria. RESULTS: A total of 505 patients were included from 1983 to 1989, and 179 from 2004 to 2005. A diagnosis was reached in 410 (81.1%) and 109 patients (60.9%), respectively. The cause of FID was an infectious disease in 389 patients from the first period (94.8% of those with a final diagnosis) and 92 from the second (84.4%). Most were systemic infections, 328 (80%) in 1983-1989 and 74 (67.8%) in 2004-2005, followed by focal infections, 9.5% and 16.5%, respectively. Q fever was the most frequent etiology in both periods. In 2004-2005, brucellosis decreased and HIV infection emerged as a cause of FID. The origin of FID was non-infectious in 5.1% and 15.5%, respectively. CONCLUSIONS: Q fever is the most frequent cause of FID in southern Spain. Studies over time are needed to identify changes in the etiologic spectrum of this condition. Important viral etiologies, such as HIV infection, may be detected as causes of FID. Further studies are needed to determine the importance of other agents as causes of FID.
Subject(s)
Fever/etiology , Adult , Female , Fever/diagnosis , Fever/microbiology , Humans , Male , Prospective Studies , Time FactorsSubject(s)
Chagas Disease/complications , Esophageal Diseases/etiology , Gastrointestinal Diseases/etiology , Chagas Cardiomyopathy/complications , Chagas Disease/diagnosis , Chagas Disease/epidemiology , Chagas Disease/therapy , Combined Modality Therapy , Comorbidity , Diagnostic Techniques, Digestive System , Emigrants and Immigrants/statistics & numerical data , Endoscopy, Digestive System , Esophageal Achalasia/diagnosis , Esophageal Achalasia/etiology , Esophageal Achalasia/parasitology , Esophageal Achalasia/pathology , Esophageal Achalasia/therapy , Esophageal Diseases/diagnosis , Esophageal Diseases/parasitology , Esophageal Diseases/pathology , Esophageal Diseases/therapy , Gastrointestinal Diseases/diagnosis , Gastrointestinal Diseases/parasitology , Gastrointestinal Diseases/pathology , Gastrointestinal Diseases/therapy , Gastrointestinal Motility , Helicobacter Infections/epidemiology , Humans , Intestinal Diseases, Parasitic/epidemiology , Latin America/ethnology , Megacolon/diagnosis , Megacolon/etiology , Megacolon/parasitology , Megacolon/pathology , Megacolon/therapy , Spain/epidemiology , Trypanocidal Agents/therapeutic use , Trypanosoma cruziABSTRACT
Chagas' disease, or American trypanosomiasis, is a parasitic zoonosis found only in the Americas. Under natural conditions, Trypanosoma cruzi is transmitted by insects belonging to different species of Triatoma. However, several routes of transmission that do not involve insect vectors have also been described, such as transmission via blood products or transplantation of infected organs, and vertical transmission. At present, the number of people infected with Chagas' disease worldwide is estimated to be about 10-12 million. The process of urbanization in Latin America and migratory population movements from endemic countries have led to the disease being diagnosed in non-endemic areas. It is estimated that 20-30% of individuals infected with T. cruzi will develop symptomatic heart disease at some point during their lives. The specific differential characteristics of chronic chagasic cardiopathy, lack of knowledge of the disease among many healthcare workers, and the fact that arrhythmia or sudden death is frequently the first manifestation of disease all make it essential that diagnostic and therapeutic protocols for the disease are developed and disseminated. The aim should be to improve patient care by increasing understanding of the condition by physicians and other healthcare professionals who may be involved in its detection and treatment.
ABSTRACT
La enfermedad de Chagas o tripanosomiasis americana es una parasitosis originaria del continente americano. En la naturaleza, Trypanosoma cruzi se transmite vectorialmente a través de diversas especies de chinches triatominos. No obstante, se han descrito otros mecanismos de transmisión no vectorial, como la transmisión a través de productos sanguíneos o mediante el trasplante de órganos infectados, y la transmisión vertical. Actualmente, la enfermedad de Chagas afecta a unos 10-12 millones de personas en el mundo y el proceso de urbanización en América Latina y los movimientos migratorios desde los países endémicos han posibilitado que la enfermedad de Chagas sea diagnosticada en zonas donde la infección no es endémica. Se considera que un 20-30% de las personas infectadas por T. cruzi desarrollarán a lo largo de su vida alteraciones cardíacas. Las características diferenciales de la cardiopatía chagásica, el escaso conocimiento que se tiene de ella en nuestro medio y la elevada frecuencia de arritmias y muerte súbita como primeras manifestaciones potenciales de esta enfermedad hacen prioritarias la elaboración y divulgación de protocolos diagnósticos y terapéuticos para la atención de estos pacientes a fin de mejorar el conocimiento de esta patología por los profesionales sanitarios potencialmente implicados en su detección y manejo (AU)
Chagas' disease, or American trypanosomiasis, is a parasitic zoonosis found only in the Americas. Under natural conditions, Trypanosoma cruzi is transmitted by insects belonging to different species of Triatoma. However, several routes of transmission that do not involve insect vectors have also been described, such as transmission via blood products or transplantation of infected organs, and vertical transmission. At present, the number of people infected with Chagas' disease worldwide is estimated to be about 10-12 million. The process of urbanization in Latin America and migratory population movements from endemic countries have led to the disease being diagnosed in non-endemic areas. It is estimated that 20-30% of individuals infected with T. cruzi will develop symptomatic heart disease at some point during their lives. The specific differential characteristics of chronic chagasic cardiopathy, lack of knowledge of the disease among many healthcare workers, and the fact that arrhythmia or sudden death is frequently the first manifestation of disease all make it essential that diagnostic and therapeutic protocols for the disease are developed and disseminated. The aim should be to improve patient care by increasing understanding of the condition by physicians and other healthcare professionals who may be involved in its detection and treatment (AU)
Subject(s)
Humans , Chagas Cardiomyopathy/diagnosis , Chagas Cardiomyopathy/drug therapy , Trypanosoma cruzi/pathogenicity , Trypanosoma cruzi/isolation & purification , Diagnosis, Differential , Arrhythmias, Cardiac/etiology , Death, Sudden, Cardiac/etiology , Electrocardiography/methods , Echocardiography/methods , Electrophysiologic Techniques, Cardiac/methodsABSTRACT
Chagas' disease, or American trypanosomiasis, is a parasitic zoonosis found only in the Americas. Under natural conditions, Trypanosoma cruzi is transmitted by insects belonging to different species of Triatoma. However, several routes of transmission that do not involve insect vectors have also been described, such as transmission via blood products or transplantation of infected organs, and vertical transmission. At present, the number of people infected with Chagas' disease worldwide is estimated to be about 10-12 million. The process of urbanization in Latin America and migratory population movements from endemic countries have led to the disease being diagnosed in non-endemic areas. It is estimated that 20-30% of individuals infected with T. cruzi will develop symptomatic heart disease at some point during their lives. The specific differential characteristics of chronic chagasic cardiopathy, lack of knowledge of the disease among many healthcare workers, and the fact that arrhythmia or sudden death is frequently the first manifestation of disease all make it essential that diagnostic and therapeutic protocols for the disease are developed and disseminated. The aim should be to improve patient care by increasing understanding of the condition by physicians and other healthcare professionals who may be involved in its detection and treatment.
Subject(s)
Chagas Cardiomyopathy/diagnosis , Chagas Cardiomyopathy/therapy , Animals , Chagas Cardiomyopathy/complications , Humans , Trypanosoma cruziABSTRACT
La enfermedad de Chagas o tripanosomiasis americana es una parasitosis originaria del continente americano. En la naturaleza, Trypanosoma cruzi se transmite vectorialmente a través de diversas especies de chinches triatominos. No obstante, se han descrito otros mecanismos de transmisión no vectorial, como la transmisión a través de productos sanguíneos o mediante el trasplante de órganos infectados, y la transmisión vertical. Actualmente, la enfermedad de Chagas afecta a unos 10-12 millones de personas en el mundo y el proceso de urbanización en América Latina y los movimientos migratorios desde los países endémicos han posibilitado que la enfermedad de Chagas sea diagnosticada en zonas donde la infección no es endémica. Se considera que un 20-30% de las personas infectadas por T. cruzi desarrollarán a lo largo de su vida alteraciones cardiacas. Las características diferenciales de la cardiopatía chagásica, el escaso conocimiento que se tiene de ella en nuestro medio y la elevada frecuencia de arritmias y muerte súbita como primeras manifestaciones potenciales de esta enfermedad hacen prioritarias la elaboración y divulgación de protocolos diagnósticos y terapéuticos para la atención de estos pacientes a fin de mejorar el conocimiento de esta patología por los profesionales sanitarios potencialmente implicados en su detección y manejo
Chagas' disease, or American trypanosomiasis, is a parasitic zoonosis found only in the Americas. Under natural conditions, Trypanosoma cruzi is transmitted by insects belonging to different species of Triatoma. However, several routes of transmission that do not involve insect vectors have also been described, such as transmission via blood products or transplantation of infected organs, and vertical transmission. At present, the number of people infected with Chagas' disease worldwide is estimated to be about 10-12 million. The process of urbanization in Latin America and migratory population movements from endemic countries have led to the disease being diagnosed in non-endemic areas. It is estimated that 20-30% of individuals infected with T. cruzi will develop symptomatic heart disease at some point during their lives. The specific differential characteristics of chronic chagasic cardiopathy, lack of knowledge of the disease among many healthcare workers, and the fact that arrhythmia or sudden death is frequently the first manifestation of disease all make it essential that diagnostic and therapeutic protocols for the disease are developed and disseminated. The aim should be to improve patient care by increasing understanding of the condition by physicians and other healthcare professionals who may be involved in its detection and treatment
Subject(s)
Humans , Trypanosoma cruzi/isolation & purification , Chagas Cardiomyopathy/diagnosis , Trypanosoma cruzi/pathogenicity , Disease Vectors , Death, Sudden/etiology , Clinical Diagnosis , Ventricular Dysfunction/etiology , Clinical Protocols , Electrocardiography , Natural History of Diseases , Chagas Cardiomyopathy/complications , Chagas Cardiomyopathy/therapy , Chagas Cardiomyopathy/transmissionSubject(s)
Malaria/epidemiology , Travel , Adult , Dominican Republic/epidemiology , Humans , Malaria/parasitology , MaleSubject(s)
Infections/etiology , Liver Transplantation , Postoperative Complications , Animals , Drug Resistance, Microbial , Forecasting , Humans , Immunosuppression Therapy/adverse effects , Incidence , Infection Control , Infections/epidemiology , Infections/transmission , Liver Transplantation/statistics & numerical data , Postoperative Complications/epidemiology , Risk Factors , Spain/epidemiology , Transplantation, Heterologous/adverse effectsABSTRACT
Using a repetitive extragenic palindromic PCR (REP-PCR), we genotypically characterized strains causing nosocomial Acinetobacter baumannii infections and analyzed the source of bacteremia in 67 patients from an institution in which infections by this bacterium were endemic. Six different genotypes were found, including 21, 27, 3, 9, 3, and 4 strains. The probable source of bacteremia, according to clinical and/or microbiological criteria, was known in 42 patients (63%): respiratory tract (n = 19), surgical sites (n = 12), intravascular catheters (n = 5), burns (n = 3), and urinary tract (n = 3). The definite source of bacteremia, according to REP-PCR, could be established in 30 (71%) out of the 42 patients with strains from blood and other sites; in these cases clinical and microbiological criteria for the source of bacteremia were thus confirmed. In the remaining 12 patients (29%) the probable source was refuted by the REP-PCR method. The definite sources of bacteremia according to genotype were as follows: respiratory tract in 13 patients (31%), surgical sites in 8 (19%), intravascular catheters in 4 (9%), burns in 3 (7%), and urinary tract in 2 (5%). A comparison of strains from blood cultures and other sites with regard to their REP-PCR and antimicrobial resistance profiles was also made. Taking the REP-PCR as the "gold standard," the positive predictive value of antibiotype was 77% and the negative predictive value was 42%. In summary, the utility of the diagnosis of the source of nosocomial A. baumannii bacteremia using clinical and/or microbiological criteria, including antibiotyping, is limited, as demonstrated by REP-PCR.
Subject(s)
Acinetobacter baumannii/classification , Acinetobacter baumannii/genetics , Bacteremia/microbiology , Cross Infection/microbiology , Polymerase Chain Reaction/methods , Acinetobacter Infections/microbiology , Acinetobacter baumannii/drug effects , Acinetobacter baumannii/isolation & purification , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/pharmacology , Bacterial Typing Techniques , Blood/microbiology , Child , Child, Preschool , Culture Media , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Repetitive Sequences, Nucleic AcidABSTRACT
No disponible
